+ 0.00
+ 0%
+ 0.00
+ 0%

Pfizer's Late-Stage COVID-19 Vaccine Data In Adolescents Reinforces Bull Case, Analyst Says

March 31, 2021 10:29 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Pfizer's Late-Stage COVID-19 Vaccine Data In Adolescents Reinforces Bull Case, Analyst Says

Pfizer Inc. (NYSE:PFE) and its German partner BioNTech SE (NASDAQ:BNTX) announced positive results Wednesday from a late-stage study of the COVID-19 vaccine BNT162b2 in adolescents.

The Pfizer Analyst: Cantor Fitzgerald analyst Louise Chen maintained an Overweight rating on Pfizer with a $53 price target.

The Pfizer Takeaways: The positive topline results are good news for the company, underlining Pfizer's ability to pivot and innovate quickly, Chen said in a note. 

The data reinforces Cantor's positive investment thesis on the stock and view that Pfizer's pipeline is underappreciated, the analyst said. 

Related Link: The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO

BNT162b2 demonstrated 100% efficacy and robust antibody responses in 12-15-year-olds and was also well-tolerated, she said.

Pfizer and BioNTech plan to submit the data to the FDA and the European Medicines Agency in order to secure an expansion to the vaccine's emergency use authorization, Chen said.

Pfizer has also commenced a global Phase 1/2/3 study to evaluate the vaccine in children, ages 6 months to 11 years, the analyst said. The company is evaluating a two-dose schedule given about 21 days apart in three cohorts: children ages 5 to 11, 2-5 and from 6 months to 2 years, she said. 

PFE Price Action: In premarket trading Wednesday, Pfizer shares were up 0.11% to $36.16. 

Related Link: The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.

Related Articles

Pfizer-BioNTech Plan Vaccine Emergency Use Filing Within Days After Final Analysis Confirm Efficacy, Safety

Pfizer Inc. (NYSE: PFE) andBioNTech SE – ADR (NASDAQ: BNTX) have managed to stay ahead in the vaccine race by a hair's breadth. read more

4 Takeaways On Pfizer's Latest Coronavirus Data

The data shows more positives about Pfizer’s (NYSE: PFE) coronavirus vaccine candidate and remains in-line with its German partner BioNTech’s (NASDAQ: BNTX) study, according to Cantor Fitzgerald Secur read more

Moderna Analyst: Unrealistic COVID-19 Vaccine Expectations Create Unfavorable Setup

Coronavirus vaccine developer Moderna Inc's (NASDAQ: MRNA) stock was moving lower Monday after a downgrade from BofA Securities.  The Moderna Analyst: Geoff Meacham downgraded Moderna shares from Neutral to Underperform and maintained a $150 price target. read more

Pfizer Analyst Breaks Down The FDA Process For Coronavirus Vaccine Candidate

Pfizer Inc. read more